EYENOVIA INC (EYEN)

What's going on in today's session

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL...

What's going on in today's session

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024...

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and...

Tuesday 4/2 Insider Buying Report: EYEN, GTN

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023

EYEN stock results show that Eyenovia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eyenovia (NASDAQ:EYEN) just reported results for the fourth quarter of 2023.Eye...

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired...

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN)...

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Company to host an investor conference call and webcast at 4:30pm EDT...

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug...

Upcoming FDA decision: Eyenovia’s APP13007

Eyenovia's (EYEN) APP13007 is coming up for a FDA decision next week. Will the drug win approval?

FDA approves Eyenovia manufacturing facility in Redwood City (NASDAQ:EYEN)

Eyenovia (EYEN) said the FDA has approved its facility in Redwood City, Calif., as a commercial manufacturing facility. Read more here.

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce...

Monday Sector Leaders: Drugs, Vehicle Manufacturers

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its...

7 Promising Penny Stocks With the Potential to Defy Expectations

While market speculation can get extremely dangerous, those who understand the risks may like these high-potential penny stocks.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage!

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK,...

NASDAQ:EYEN Investor Notice: Investigation over Potential Wrongdoing at Eyenovia, Inc.

San Diego, CA -- (SBWIRE) -- 10/11/2023 -- Certain directors of Eyenovia, Inc. are under investigation over potential breaches of fiduciary duties.

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presentation...

Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™...

Eyenovia to raise capital via ~$12M securities offering (NASDAQ:EYEN)

Eyenovia (EYEN) has entered into a definitive pact with certain investors for the issuance and sale of 4,198,633 of its common stock, pre-funded warrants to purchase up to 2,252,979...